280 related articles for article (PubMed ID: 32317605)
21. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
[TBL] [Abstract][Full Text] [Related]
22. Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.
Wakefield C; O'Keefe L; Heffron CCBB
Virchows Arch; 2023 Dec; 483(6):847-854. PubMed ID: 37723345
[TBL] [Abstract][Full Text] [Related]
23. Use of New Techniques in Addition to IHC Applied to the Diagnosis of Melanocytic Lesions, With Emphasis on CGH, FISH, and Mass Spectrometry.
Nagarajan P; Tetzlaff MT; Curry JL; Prieto VG
Actas Dermosifiliogr; 2017; 108(1):17-30. PubMed ID: 27344067
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
[TBL] [Abstract][Full Text] [Related]
25. Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation.
Fattori A; de la Fouchardière A; Cribier B; Mitcov M
Hum Pathol; 2022 Mar; 121():19-28. PubMed ID: 34990622
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma.
See SHC; Finkelman BS; Yeldandi AV
Pathol Res Pract; 2020 Sep; 216(9):153105. PubMed ID: 32825968
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic utility of PRAME in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi.
Gill P; Prieto VG; Austin MT; Giubellino A; Torres-Cabala CA
J Cutan Pathol; 2021 Nov; 48(11):1410-1415. PubMed ID: 34164835
[TBL] [Abstract][Full Text] [Related]
28. Fluorescence in situ hybridization (FISH) analysis of melanocytic nevi and melanomas: sensitivity, specificity, and lack of association with sentinel node status.
Fang Y; Dusza S; Jhanwar S; Busam KJ
Int J Surg Pathol; 2012 Oct; 20(5):434-40. PubMed ID: 22561674
[TBL] [Abstract][Full Text] [Related]
29. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
30. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
Turner N; Ko CJ; McNiff JM; Galan A
Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
[TBL] [Abstract][Full Text] [Related]
31. PRAME expression in melanocytic lesions of the conjunctiva.
Šekoranja D; Hawlina G; Pižem J
Histopathology; 2021 Dec; 79(6):989-996. PubMed ID: 34268800
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression of HMB45 and negative PRAME expression in halo nevi.
Ruby KN; Li Z; Yan S
J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871
[TBL] [Abstract][Full Text] [Related]
33. Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma.
Clarke LE; Pimentel JD; Zalaznick H; Wang L; Busam KJ
Hum Pathol; 2017 Dec; 70():113-120. PubMed ID: 29079183
[TBL] [Abstract][Full Text] [Related]
34. Deep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.
Magro CM; Abraham RM; Guo R; Li S; Wang X; Proper S; Crowson AN; Mihm M
Eur J Dermatol; 2014; 24(5):594-602. PubMed ID: 25118781
[TBL] [Abstract][Full Text] [Related]
35. β-Catenin nuclear expression discriminates deep penetrating nevi from other cutaneous melanocytic tumors.
de la Fouchardière A; Caillot C; Jacquemus J; Durieux E; Houlier A; Haddad V; Pissaloux D
Virchows Arch; 2019 May; 474(5):539-550. PubMed ID: 30756182
[TBL] [Abstract][Full Text] [Related]
36. PRAME expression in cutaneous melanoma does not correlate with disease-specific survival.
Parra O; Ma W; Li Z; Coffing BN; Linos K; LeBlanc RE; Momtahen S; Sriharan A; Cloutier JM; Wells WA; Yan S
J Cutan Pathol; 2023 Oct; 50(10):903-912. PubMed ID: 37430414
[TBL] [Abstract][Full Text] [Related]
37. The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas.
Uguen A; Uguen M; Guibourg B; Talagas M; Marcorelles P; De Braekeleer M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):361-367. PubMed ID: 27490764
[TBL] [Abstract][Full Text] [Related]
38. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
39. Reduced H3K27me3 Expression Is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules.
Busam KJ; Shah KN; Gerami P; Sitzman T; Jungbluth AA; Kinsler V
Am J Surg Pathol; 2017 Mar; 41(3):396-404. PubMed ID: 27849631
[TBL] [Abstract][Full Text] [Related]
40. HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).
Grillini M; Ricci C; Pino V; Pedrini S; Fiorentino M; Corti B
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):14-18. PubMed ID: 34508017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
